<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00033358</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-00466</org_study_id>
    <secondary_id>ID01-340</secondary_id>
    <secondary_id>CDR0000069277</secondary_id>
    <secondary_id>NCI-P02-0218</secondary_id>
    <secondary_id>MDA-ID-01340</secondary_id>
    <secondary_id>N01CN05127</secondary_id>
    <nct_id>NCT00033358</nct_id>
  </id_info>
  <brief_title>Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer</brief_title>
  <official_title>Modulation Of Putative Surrogate Endpoint Biomarkers In Endometrial Biopsies From Women With HNPCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Randomized phase II trial to compare two different hormone therapy regimens in preventing&#xD;
      endometrial cancer in women who have a genetic risk for hereditary nonpolyposis colon cancer.&#xD;
      Hormone therapy may prevent the development of endometrial cancer in women with a genetic&#xD;
      risk for hereditary nonpolyposis colon cancer. It is not yet known which hormone therapy&#xD;
      regimen is more effective in preventing endometrial cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. The primary objective is to evaluate the effect of progesterone therapy versus combination&#xD;
      estrogen and progesterone therapy on potential surrogate endpoint biomarkers (SEBs) relevant&#xD;
      to endometrial carcinogenesis.&#xD;
&#xD;
      II. To evaluate changes in histology and ultrasound appearance of the endometrium in women&#xD;
      with HNPCC after 3 months of progesterone therapy versus combination estrogen and&#xD;
      progesterone therapy compared with baseline.&#xD;
&#xD;
      III. To establish a point estimate of the baseline frequency of endometrial abnormalities&#xD;
      looking at histological and molecular markers in a cohort of females carrying an HNPCC gene&#xD;
      mutation.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      All patients undergo a baseline transvaginal ultrasound and endometrial biopsy.&#xD;
&#xD;
      Arm I: Patients receive medroxyprogesterone intramuscularly once on day 1. Approximately 90&#xD;
      days after the injection, patients undergo a repeat transvaginal ultrasound and endometrial&#xD;
      biopsy.&#xD;
&#xD;
      Arm II: Patients receive oral contraceptive pills (OCP) comprising ethinyl estradiol and&#xD;
      norgestrel once daily on days 1-21. Treatment repeats every 28 days for 3-4 courses (3-4&#xD;
      packs of OCP) in the absence of unacceptable toxicity. Approximately 1 week after starting&#xD;
      the fourth pack of OCP, patients undergo a repeat transvaginal ultrasound and endometrial&#xD;
      biopsy.&#xD;
&#xD;
      Patients are followed at 6 weeks and are encouraged to return in 6 months to participate in&#xD;
      continued endometrial screening.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in potential SEBs relevant to endometrial carcinogenesis.</measure>
    <time_frame>From baseline to completion of hormone therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in histology and ultrasound appearance of the endometrium in women with HNPCC</measure>
    <time_frame>From baseline to 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (medroxyprogesterone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive medroxyprogesterone intramuscularly once on day 1. Approximately 90 days after the injection, patients undergo a repeat transvaginal ultrasound and endometrial biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (ethinyl estradiol, norgestrel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive OCP comprising ethinyl estradiol and norgestrel once daily on days 1-21. Treatment repeats every 28 days for 3-4 courses (3-4 packs of OCP) in the absence of unacceptable toxicity. Approximately 1 week after starting the fourth pack of OCP, patients undergo a repeat transvaginal ultrasound and endometrial biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>medroxyprogesterone</intervention_name>
    <description>Given intramuscularly</description>
    <arm_group_label>Arm I (medroxyprogesterone)</arm_group_label>
    <other_name>Depo-Provera</other_name>
    <other_name>medroxyprogesterone acetate</other_name>
    <other_name>MPA</other_name>
    <other_name>Provera</other_name>
    <other_name>Provera Dosepak</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ethinyl estradiol</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II (ethinyl estradiol, norgestrel)</arm_group_label>
    <other_name>Diogyn E</other_name>
    <other_name>EE</other_name>
    <other_name>Estinyl</other_name>
    <other_name>Ethinoral</other_name>
    <other_name>Eticylol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>norgestrel</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II (ethinyl estradiol, norgestrel)</arm_group_label>
    <other_name>Microlut</other_name>
    <other_name>NORGES</other_name>
    <other_name>Ovrette</other_name>
    <other_name>Wy-3707</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (medroxyprogesterone)</arm_group_label>
    <arm_group_label>Arm II (ethinyl estradiol, norgestrel)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with known mutation of an HNPCC-associated gene (hMLH-1, hMSH-2, or hMSH-6) or&#xD;
             fulfill Amsterdam Criteria and have had one or more HNPCC-associated cancers&#xD;
&#xD;
          -  No prior hysterectomy; (participants may be scheduled for prophylactic hysterectomy&#xD;
             following the study)&#xD;
&#xD;
          -  Voluntary consent documented by a signed and witnessed informed consent&#xD;
&#xD;
          -  Negative serum pregnancy test at baseline evaluation&#xD;
&#xD;
          -  No history of pelvic irradiation for whatever cause&#xD;
&#xD;
          -  No chemotherapy for two years&#xD;
&#xD;
          -  Women &gt;= 40 must have had a screening mammogram within the last 12 months prior to&#xD;
             participation in this study&#xD;
&#xD;
          -  Women who are at 50% risk of having a mutation and willing to have genetic testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of oral contraceptives or depoMPA or hormonal exposure, such as hormonal IUD,&#xD;
             tamoxifen, raloxifene, or other selective estrogen receptor modulators (SERMs) within&#xD;
             four months of initiating study; women will be asked to be off oral contraceptives or&#xD;
             other hormonal exposure for 4 months prior to initiating study&#xD;
&#xD;
          -  Medical contraindication to use of oral contraceptives or depoMPA including:&#xD;
&#xD;
               -  Known or suspected pregnancy&#xD;
&#xD;
               -  Undiagnosed vaginal bleeding&#xD;
&#xD;
               -  Known or suspected malignancy of breast or endometrium&#xD;
&#xD;
               -  Active thrombophlebitis, or current or past history of thromboembolic disorders,&#xD;
                  or cerebral vascular disease&#xD;
&#xD;
               -  Gall bladder disease or liver dysfunction or disease, including hepatic adenomas&#xD;
                  or carcinoma, or abnormal liver function tests&#xD;
&#xD;
               -  Known hypersensitivity to depoMPA contraceptive injection (medroxyprogesterone&#xD;
                  acetate or any of its other ingredients)&#xD;
&#xD;
               -  Depression that is currently not under control, in the judgement of the Principal&#xD;
                  Investigator&#xD;
&#xD;
               -  History of epilepsy&#xD;
&#xD;
               -  History of diabetes&#xD;
&#xD;
               -  Coronary artery disease&#xD;
&#xD;
               -  Age &gt;=35 and a current tobacco smoker&#xD;
&#xD;
          -  Known inability to participate in the scheduled follow-up tests (i.e., alcohol&#xD;
             dependence or illicit drug use)&#xD;
&#xD;
          -  Significant medical history or psychiatric problems which would make the participant a&#xD;
             poor protocol candidate, in the opinion of the principal investigator&#xD;
&#xD;
          -  Post surgical removal of both ovaries&#xD;
&#xD;
          -  Postmenopausal women with amenorrhea greater than 12 months&#xD;
&#xD;
          -  Previous history of endometrial biopsy, hysteroscopy, dilatation and curettage, or IUD&#xD;
             in place within the past 3 months&#xD;
&#xD;
          -  Known participation in a concurrent protocol with a pharmacological intervention&#xD;
&#xD;
          -  Recent or concurrent use of systemic steroids (i.e. prednisone) within the past four&#xD;
             months of initiating study&#xD;
&#xD;
          -  Positive serum pregnancy test at baseline evaluation&#xD;
&#xD;
          -  Fasting triglycerides level &gt;= 400 mg/dl&#xD;
&#xD;
          -  Cholesterol level &gt;= 240 mg/dl&#xD;
&#xD;
          -  LDL level &gt;= 160 mg/dl&#xD;
&#xD;
          -  HDL level =&lt; 35 mg/dl&#xD;
&#xD;
          -  Hypertension that is currently not under good control, in the judgement of the&#xD;
             principal investigator&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Lu</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>April 9, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 2, 2013</last_update_submitted>
  <last_update_submitted_qc>May 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Norgestrel</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

